Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255098488> ?p ?o ?g. }
Showing items 1 to 94 of
94
with 100 items per page.
- W4255098488 endingPage "01" @default.
- W4255098488 startingPage "P3" @default.
- W4255098488 abstract "Abstract Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor. Results from the randomized, placebo-controlled, Phase III ExteNET study demonstrated that neratinib significantly improves 24-month iDFS in patients (pts) with trastuzumab-treated early-stage HER2+ breast cancer (HR 0.67; 95% CI 0.50–0.91; p=0.009) [Chan et al. Lancet Oncol 2016]. In ExteNET, loperamide prophylaxis was not mandated, and diarrhea was the most commonly observed toxicity (grade 3, 39.8%). To reduce neratinib-associated diarrhea, high-dose loperamide prophylaxis given with the first 1–2 cycles of neratinib has been incorporated into all neratinib clinical trials; available data suggest that loperamide prophylaxis reduces the incidence and median cumulative duration of higher-grade neratinib-related diarrhea. CONTROL is an international, open-label, sequential cohort, phase II study investigating the effects of prophylaxis with loperamide ± the long-acting corticosteroid budesonide or bile acid sequestrant colestipol on neratinib-associated diarrhea. We present updated data from this study. Methods: Pts with stage 1–3c HER2+ breast cancer who completed trastuzumab-based adjuvant therapy within 1 year were eligible. All pts received oral neratinib 240 mg once daily for 1 year + oral loperamide prophylaxis for 1 or 2 cycles (1 cycle = 28 days) ± budesonide or colestipol for the first cycle (see table). Adverse events were graded according to NCI-CTCAE (v4.0). Primary endpoint: incidence of grade ≥3 diarrhea. Results: StudyCONTROLExteNET5Cohort or study armLoperamideBudesonideColestipolNeratinibAntidiarrheal prophylaxisLoperamide1,2Budesonide + loperamide2,3Colestipol + loperamide2,4Loperamide prnN (at data cut-off)137664391408Diarrhea, % Any grade78.179.753.895.4Grade 124.125.025.622.9Grade 223.429.720.532.5Grade 330.725.07.739.8Grade 40000.1Median cumulative duration of diarrhea, days Any grade12.013.011.059.0Grade ≥24.03.02.010.0Grade ≥373.02.04.05.0Median episodes of diarrhea per patient, n Any grade2.04.03.08.0Grade ≥22.02.01.03.0Grade ≥371.01.02.02.0Neratinib discontinuation (due to diarrhea), %20.49.4016.8Hospitalization, %1.5001.4Median duration of neratinib treatment, mo811.06.32.111.61. Oral loperamide 4 mg, then 2 mg q4h d1-3, then 2 mg q6-8h d4-56 (original); 2. Oral loperamide 4 mg, then 4 mg tid d1-14, then 4 mg bid d15-56 (modified); 3. Oral budesonide 9 mg qd d1-28; 4. Oral colestipol 2 g qd d1-28; 5. Chan et al. Lancet Oncol 2016; 6. Original,1 n=28; modified,2 n=109; 7. Grade 4 events: CONTROL, n=0; ExteNET, n=1; 8. Treatment ongoing in all CONTROL cohorts. CONTROL data cut-off: Apr 2017. Conclusions: A structured loperamide prophylactic regimen for 1 or 2 cycles reduces the incidence, severity and duration of neratinib-associated diarrhea compared with events observed in the ExteNET trial. Adding budesonide or colestipol appears to further diminish the duration and number of episodes of diarrhea and improves neratinib tolerability. Final analysis of the CONTROL study will be performed when all pts have completed 12 months of neratinib therapy. Updated data will be available at the meeting. Clinicaltrials.gov: NCT02400476. Citation Format: Hurvitz S, Chan A, Iannotti N, Ibrahim E, Chien J, Chan N, Kellum A, Hansen V, Marx G, Kendall SD, Wilkinson M, Castrellon A, Ruiz R, Fang P, Hunt D, Moran S, Olek E, Barcenas CH, Rugo HS. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-14-01." @default.
- W4255098488 created "2022-05-12" @default.
- W4255098488 creator A5004870614 @default.
- W4255098488 creator A5005769474 @default.
- W4255098488 creator A5007327429 @default.
- W4255098488 creator A5009477344 @default.
- W4255098488 creator A5021913157 @default.
- W4255098488 creator A5026987682 @default.
- W4255098488 creator A5029214614 @default.
- W4255098488 creator A5035216973 @default.
- W4255098488 creator A5044363769 @default.
- W4255098488 creator A5049202015 @default.
- W4255098488 creator A5049358292 @default.
- W4255098488 creator A5058019518 @default.
- W4255098488 creator A5064106888 @default.
- W4255098488 creator A5069043926 @default.
- W4255098488 creator A5072917229 @default.
- W4255098488 creator A5078184758 @default.
- W4255098488 creator A5080396033 @default.
- W4255098488 creator A5081598358 @default.
- W4255098488 creator A5081735541 @default.
- W4255098488 date "2018-02-15" @default.
- W4255098488 modified "2023-09-27" @default.
- W4255098488 title "Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial" @default.
- W4255098488 doi "https://doi.org/10.1158/1538-7445.sabcs17-p3-14-01" @default.
- W4255098488 hasPublicationYear "2018" @default.
- W4255098488 type Work @default.
- W4255098488 citedByCount "10" @default.
- W4255098488 countsByYear W42550984882018 @default.
- W4255098488 countsByYear W42550984882019 @default.
- W4255098488 countsByYear W42550984882020 @default.
- W4255098488 countsByYear W42550984882021 @default.
- W4255098488 crossrefType "journal-article" @default.
- W4255098488 hasAuthorship W4255098488A5004870614 @default.
- W4255098488 hasAuthorship W4255098488A5005769474 @default.
- W4255098488 hasAuthorship W4255098488A5007327429 @default.
- W4255098488 hasAuthorship W4255098488A5009477344 @default.
- W4255098488 hasAuthorship W4255098488A5021913157 @default.
- W4255098488 hasAuthorship W4255098488A5026987682 @default.
- W4255098488 hasAuthorship W4255098488A5029214614 @default.
- W4255098488 hasAuthorship W4255098488A5035216973 @default.
- W4255098488 hasAuthorship W4255098488A5044363769 @default.
- W4255098488 hasAuthorship W4255098488A5049202015 @default.
- W4255098488 hasAuthorship W4255098488A5049358292 @default.
- W4255098488 hasAuthorship W4255098488A5058019518 @default.
- W4255098488 hasAuthorship W4255098488A5064106888 @default.
- W4255098488 hasAuthorship W4255098488A5069043926 @default.
- W4255098488 hasAuthorship W4255098488A5072917229 @default.
- W4255098488 hasAuthorship W4255098488A5078184758 @default.
- W4255098488 hasAuthorship W4255098488A5080396033 @default.
- W4255098488 hasAuthorship W4255098488A5081598358 @default.
- W4255098488 hasAuthorship W4255098488A5081735541 @default.
- W4255098488 hasConcept C121608353 @default.
- W4255098488 hasConcept C126322002 @default.
- W4255098488 hasConcept C143998085 @default.
- W4255098488 hasConcept C197934379 @default.
- W4255098488 hasConcept C2777573665 @default.
- W4255098488 hasConcept C2779413316 @default.
- W4255098488 hasConcept C2779786085 @default.
- W4255098488 hasConcept C2779802037 @default.
- W4255098488 hasConcept C530470458 @default.
- W4255098488 hasConcept C71924100 @default.
- W4255098488 hasConcept C90924648 @default.
- W4255098488 hasConceptScore W4255098488C121608353 @default.
- W4255098488 hasConceptScore W4255098488C126322002 @default.
- W4255098488 hasConceptScore W4255098488C143998085 @default.
- W4255098488 hasConceptScore W4255098488C197934379 @default.
- W4255098488 hasConceptScore W4255098488C2777573665 @default.
- W4255098488 hasConceptScore W4255098488C2779413316 @default.
- W4255098488 hasConceptScore W4255098488C2779786085 @default.
- W4255098488 hasConceptScore W4255098488C2779802037 @default.
- W4255098488 hasConceptScore W4255098488C530470458 @default.
- W4255098488 hasConceptScore W4255098488C71924100 @default.
- W4255098488 hasConceptScore W4255098488C90924648 @default.
- W4255098488 hasIssue "4_Supplement" @default.
- W4255098488 hasLocation W42550984881 @default.
- W4255098488 hasOpenAccess W4255098488 @default.
- W4255098488 hasPrimaryLocation W42550984881 @default.
- W4255098488 hasRelatedWork W122747164 @default.
- W4255098488 hasRelatedWork W2171650890 @default.
- W4255098488 hasRelatedWork W2372652027 @default.
- W4255098488 hasRelatedWork W2807218431 @default.
- W4255098488 hasRelatedWork W3027663151 @default.
- W4255098488 hasRelatedWork W4212889635 @default.
- W4255098488 hasRelatedWork W4220783996 @default.
- W4255098488 hasRelatedWork W4286297057 @default.
- W4255098488 hasRelatedWork W4289262139 @default.
- W4255098488 hasRelatedWork W4321782412 @default.
- W4255098488 hasVolume "78" @default.
- W4255098488 isParatext "false" @default.
- W4255098488 isRetracted "false" @default.
- W4255098488 workType "article" @default.